PERCEPTIVE ADVISORS LLC
Q3 2020 13F-HR Holdings
Net value change ($000)
+678,454
(11.0%)
New positions
28
Sold out positions
28
Turnover %
19.5%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Mirati Therapeutics, Inc. | 254,106 | 80.3% |
| OM | 142,391 | NEW |
| CRSP | 112,187 | NEW |
| RLAY | 99,209 | NEW |
| ZYMEWORKS INC | 75,833 | 58.7% |
| IMMUNOMEDICS INC | 64,725 | 504.3% |
| LONA | 57,499 | NEW |
| CHRS | 56,954 | 584.8% |
| MyoKardia, Inc. | 55,396 | 41.1% |
| NVAX | 47,508 | 162.8% |
Top Reduces (Value $000, Stocks/ETFs)
| ZOGENIX, INC. | -132,542 | -100.0% |
| KOD | -128,397 | -67.5% |
| NBIX | -112,328 | -43.0% |
| VAPOTHERM INC | -54,876 | -100.0% |
| Global Blood Therapeutics, Inc. | -48,944 | -13.3% |
| AGIO | -48,132 | -100.0% |
| BDTX | -43,996 | -100.0% |
| VYNE | -39,576 | -100.0% |
| FOLD | -25,027 | -6.6% |
| ALLO | -22,973 | -34.8% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
63,088
(0.9% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|